TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00829192
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous implant administered every 60 days
Study: NCT01016366
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vials with solution for i.v. injection. Placebo dosed 3 times per week for two weeks.
Study: NCT03018756
Drug: Fentanyl Citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mcg fentanyl citrate will be inhaled via nebulizer.
Study: NCT03018756
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline solution will be inhaled via nebulizer
Study: NCT01640834
Drug: LY2409021
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01640834
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01765218
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo identical in appearance to the active agent (topiramate)
Study: NCT01035411
Drug: AZD9668
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 30 mg batch DLE494
Study: NCT01035411
Drug: AZD9668
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 30 mg batch DLF497
Study: NCT01035411
Drug: AZD9668
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 30 mg tablet variant 1
Study: NCT00575484
Drug: Normal saline, then oral placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mL normal saline infusion X 30min BID dosed simultaneously with IV bolus furosemide BID (latter dose per treating physician) PLUS 2gm sodium diet PLUS 1.5L fluid restriction. After switch to oral diuretic, begin oral placebo capsule BID, dosed with loop diuretic (dose per treating physician) PLUS 2gm sodium diet PLUS 1.5L fluid restriction.
Study: NCT01114126
Drug: Neu-P11 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison of different dosages
Study: NCT04100902
Drug: ODACTRA 12 SQ-HDM Sublingual Tablet
Normalized name: ODACTRA 12 SQ-HDM Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects are randomized to either HDM-AIT or Placebo for 24 weeks of therapy
Study: NCT04100902
Drug: Placebo sublingual tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects are randomized to either HDM-AIT or Placebo for 24 weeks of therapy
Study: NCT04556383
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT00615927
Drug: Imatinib Mesylate & Hydroxyurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib administered orally on daily. Imatinib is local irritant \& must be taken in sitting position; mini of 2hrs should be allowed between last drug intake \& going to bed. Imatinib doses 400mg/600mg administered once daily, whereas daily doses of 800mg/\> administered as equally divided dose taken twice day. Dose for imatinib: Pts not receiving p450-inducing antiepileptic drugs: 400 mg/day. Pts receiving p450-inducing antiepileptic drugs: 500 mg twice day. It is recommended that pts take their prescribed imatinib mesylate at same time that they take their prescribed hydroxyurea, however, 30-60min interval between agents is acceptable if required for practical/other compliance issues.~Hydroxyurea administered orally twice day. Dosing will begin on day 1 of cycle 1 \& continue daily. Drug is approximately 80 percent bioavailable. Dose will be 500mg twice day for all pts.
Study: NCT02269800
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tid, 7 days
Study: NCT04128059
Drug: BVRS-GamVac-Combi
Normalized name: NexGard Combo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BVRS-GamVac-Combi, a combined vector vaccine for the prevention of Middle East respiratory syndrome, lyophilisate for the preparation of a solution for intramuscular administration
Study: NCT02762370
Drug: FX006 32 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 5 mL IA injection
Study: NCT02762370
Drug: TCA IR 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 1 mL IA injection
Study: NCT00029770
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00029770
Drug: Non-Steroidal anti-inflammatory drugs (NSAIDS)
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00246740
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: In addition to standard care, patients received oral administration of placebo twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.
Study: NCT00528697
Drug: ABT-089
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take 0.5 and 1 and/or 5 and/or 10 mg ABT-089 tablets (actual dose based on weight) once daily for 8 weeks.
Study: NCT00528697
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will take a tablet once daily for 8 weeks
Study: NCT00101452
Drug: S-adenosyl-l-methionine
Normalized name: S-Adenosyl-L-Methionine (Sam-E)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 mg per day with possibility of increasing to 3200 mg per day at 6 weeks
Study: NCT00101452
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules look like escitalopram capsules and SAMe capsules
Study: NCT01994889
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in soft gel capsules administered once a day for 30 months
Study: NCT03297710
Drug: Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00964210
Drug: Licensed quadrivalent HPV vaccine, Gardasil
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of the four valent (4v) HPV vaccine is 0.5ml administered by intramuscular (IM)injection. The recommended schedule is 0, 2 and 6 months.
Study: NCT02185924
Drug: N/S 0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01779258
Drug: glycerol, paraffin (liquid and white soft)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 application in the morning and in the evening
Study: NCT01779258
Drug: Locatop@
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the Run-In period:~1 application in the morning and in the evening during a maximum of 21 days
Study: NCT01779258
Drug: Locapred@
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the 3 months study treatment:~1 application in the evening in case of flare
Study: NCT04520451
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet or capsule
Study: NCT00054340
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00054340
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02975557
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Refresh plus Artificial Tear) dispensed in Brimonidine bottles 2 times a day for 12 weeks.
Study: NCT03423199
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Study: NCT00600977
Drug: Doxorubicine pegylated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 MG/M² J1 2 courses
Study: NCT03050229
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily before or after breakfast
Study: NCT00849095
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: bid inhaled placebo
Study: NCT02408159
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03158285
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo as SC injection.
Study: NCT02200640
Drug: High dose of Micardis®, once daily
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02200640
Drug: Low dose of Micardis®, once daily
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02200640
Drug: Low dose of COZAAR®, once daily
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02200640
Drug: High dose of COZAAR®, once daily
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02200640
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03456076
Drug: Alectnib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive alectinib 600 mg orally BID until completion of treatment period (24 months) or recurrence of disease , unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
Study: NCT03111186
Drug: Ibuprofen 400 mg
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 400 mg up to six times daily as needed for pain
Study: NCT03111186
Drug: Acetaminophen 650 mg
Normalized name: acetaminophen 650 MG
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 650 mg up to four times daily as needed for pain
Study: NCT04270370
Drug: LY3478045
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT04270370
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT03510741
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to TAU
Study: NCT03510741
Drug: Sodium Benzoate Plus N-Acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Benzoate will be administered at 1000mg daily and NAC 1000 mgs twice daily dose
Study: NCT01106716
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV Infusion
Study: NCT02879006
Drug: Chinese Herbal Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, 26 month course, starting 2 months pre-OIT
Study: NCT02879006
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules that look identical to E-B-FAHF-2, 26 month course, starting 2 months pre-OIT
Study: NCT00276458
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20mg Pbo and ezetimibe 10mg Pbo tablets po qd (by mouth, once a day). for 6 weeks
Study: NCT04000958
Drug: Regular treament
Approvals — FDA: no, EMA: no, PMDA: no
Description: The choice of inhalers depends on physician's evaluation. The medication is the same as experimental group.
Study: NCT02151552
Drug: Endotoxin (E. coli O:113, Reference Endotoxin)
Normalized name: E.COLI
Approvals — FDA: no, EMA: no, PMDA: no
Description: The endotoxin will be reconstituted with sterile water to a final concentration of 2,000 endotoxin units/ml. The dose of 4 ng/kg will be prepared to a final volume of 2 ml and will be administered using a 5F balloon-tipped monitoring catheter inserted via a fiberoptic bronchoscope into the lateral segment of the right middle lobe of the lung on the morning of Day 2.
Study: NCT02151552
Drug: [18F](+/-)NOS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 mCi of \[18F\](+/-)NOS will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
Study: NCT02879006
Drug: Multi OIT
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 months of multi OIT (maintenance dose of 1gm each food allergen)
Study: NCT00186875
Drug: methotrexate, teniposide, PEG-asparaginase
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Detailed Description section for details of treatment interventions.
Study: NCT00186875
Drug: mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Detailed Description section for details of treatment interventions.
Study: NCT00186875
Drug: L-asparaginase, erwinia asparaginase
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Detailed Description section for details of treatment interventions.
Study: NCT01923207
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, subcutaneous administration
Study: NCT03869905
Drug: Aquamin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day)
Study: NCT01311167
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of 2 mg of placebo for 4 days
Study: NCT00796926
Drug: Systane Ultra eyedrops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four times a day
Study: NCT00796926
Drug: Refresh eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four times a day
Study: NCT02878161
Drug: methotrexate(necessary)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be received orally with dosage of 10mg/ week for every patient and MTX dose must be stable for at least 4 weeks.
Study: NCT02878161
Drug: Glucocorticoids (permitted,not necessary)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoids (prednisone less than 10mg/day, or equal dosage of other similar drugs) will be permitted if the patient had received for 1 month before enrollment and the dosage will not be changed during the period.
Study: NCT02323100
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 am, 4pm and midnight
Study: NCT03992456
Drug: Trifluridine and Tipiracil Hydrochloride
Normalized name: tipiracil / trifluridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01789398
Drug: BF2.649
Approvals — FDA: no, EMA: no, PMDA: no
Description: BF2.649 is provided in capsules. Patients should take 1 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast).
Study: NCT01420094
Drug: Acetaminophen (Tylenol extra strength)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of acetaminophen (Tylenol extra strength) caplet 1000 mg (2 x 500 mg) and 2 placebo matching aspirin tablets with a full glass of water (240 mL) between 1-4 hours post dental surgery.
Study: NCT01420094
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of placebo (2 placebo aspirin tablets and 2 placebo acetaminophen caplets) with a full glass of water (240 mL) between 1-4 hours post dental surgery.
Study: NCT01901393
Drug: IV ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01901393
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00039572
Drug: boronophenylalanine-fructose complex
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02181673
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive intravenous infusions of placebo at Weeks 0, 4, 12 and 20 in treatment Group 1 and intravenous infusions of placebo at Week 24 to maintain the blind in treatment Group 2.
Study: NCT03976648
Drug: GLPG1690
Approvals — FDA: no, EMA: no, PMDA: no
Description: film-coated tablets of GLPG1690 to be administered orally
Study: NCT00296205
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01589991
Drug: Toothpaste
Normalized name: TOOTHPASTE
Approvals — FDA: no, EMA: no, PMDA: no
Description: The volunteers brushed their teeth with 0.3 g of the assigned toothpastes, 3x/day.
Study: NCT00833664
Drug: Lamisil® 250 mg Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 250 mg
Study: NCT04469998
Drug: AXR-270 Vehicle
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: AXR-270 Topical Eyelid Cream Vehicle
Study: NCT00312650
Drug: liposomal doxorubicin and gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02657473
Drug: Saline 0.9% inhalation solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00476008
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet placebo morning and evening (BID) for 12 months
Study: NCT06131476
Drug: Blink® Tears eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Drops
Study: NCT06131476
Drug: Investigational lipid eye drops
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test Drops
Study: NCT01615822
Drug: OZ439 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: OZ439 100mg oral suspension, single dose
Study: NCT01292824
Drug: ITX 5061
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITX 5061 (150mg) pre-transplant, immediately post-transplant and daily thereafter for 1 week.
Study: NCT01615822
Drug: OZ439 400mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: OZ439 400mg oral suspension, single dose
Study: NCT01615822
Drug: MQ 250 mg, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine 250 mg tablet, single dose
Study: NCT01615822
Drug: MQ 750mg, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine 750mg oral tablet, single dose
Study: NCT01615822
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00539006
Drug: FPNS
Normalized name: Fluticasone Propionate and Salmeterol
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: fluticasone propionate nasal spray
Study: NCT00539006
Drug: placebo FPNS
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo nasal spray matching fluticasone propionate nasal spray
Study: NCT01764776
Drug: LDE225
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDE225
Study: NCT03921645
Drug: aerosol antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: use of inhaled Antibacterial drug combined with intravenous antibiotics to treatment multiple drug resistance GNB ventilator associated pneumonia.
Study: NCT01357850
Drug: GSK716155
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK716155
Study: NCT01357850
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04546984
Drug: HEC96719
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 2：Mulltiple doses up to 10 days
Study: NCT04274998
Drug: [18F]NOS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Main Study: PET/CT imaging will be used to evaluate neuroinflammation in the brain using the investigational radiotracer \[18F\]NOS.
Study: NCT04274998
Drug: [11C]PBR28
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-Study: Additional PET/CT imaging will be used to evaluate neuroinflammation in the brain for subjects with specific genetic polymorphism using the investigational radiotracer \[11C\]PBR28 in comparison to \[18F\]NOS.
Study: NCT01310205
Drug: SCV-07
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an extension of ongoing study SCI-SCV-HCV-P2-001. Subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with peg-IFN and RBV
Study: NCT02891070
Drug: FS VH S/D 500 s-apr
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01874340
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered at predefined visits over the 6-month treatment phase.
Study: NCT01874340
Drug: AIN457
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIN457 will be administered at predefined visits over the 6-month treatment phase.
Study: NCT01132781
Drug: Theophylline (Intervention Group)
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg twice daily of slow release theophylline
Study: NCT01132781
Drug: Placebo (Placebo Group)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg twice daily of placebo drug
Study: NCT03926611
Drug: Placebo arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo, orally, twice daily from Day 1 to 85
Study: NCT00389987
Drug: MK0826, /Duration of Treatment : 8 Weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003452
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Stage IV Bladder Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT01146327
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple oral doses of placebo will be given once daily for 2 weeks.
Study: NCT00484757
Drug: Orexine A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06354127
Drug: Botox®
Approvals — FDA: no, EMA: no, PMDA: no
Description: The test drug or control drug is injected on the day of administration.
Study: NCT01652482
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard Leucovorin chemotherapy (400 mg/m\^2 \[racemic form\] or 200 mg/m\^2 \[L-isomer form\] administered by intravenous infusion over 120 +/- 10 minutes) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
Study: NCT01652482
Drug: MEHD7945A
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEHD7945A 1100 milligram (mg) intravenous infusion every 2 weeks until documented disease progression or unacceptable toxicity.
Study: NCT00481091
Drug: ABT-263
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet; Oral
Study: NCT00475306
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01042041
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given via transarterial/hepatic chemoembolization
Study: NCT03176537
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Androgel (50mg testosterone), gel, daily
Study: NCT03176537
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, gel, daily
Study: NCT02195271
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01490905
Drug: Theraprofen
Normalized name: Theraprofen-90 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theramine two capsules twice daily and ibuprofen 400mg once daily for 28 days.
Study: NCT01490905
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 400mg once daily for 28 days.
Study: NCT02536417
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: To determine the effectiveness of melatonin in preventing the development of delirium compared with placebo